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Summary 
The cell-triggering properties of BCR, TCR and FcR 
depend on structurally related immunoreceptor tyro- 
sine-based activation motifs (ITAMs). FcyRllB have no 
ITAM and do not trigger cell activation. When coag- 
gregated to BCR, they inhibit B cell activation. We 
show here that, when coaggregated to these recep 
tors, FcyRllB inhibit FceRI-, FcyRIIA-, and TCR-depen- 
dent cell activation. Inhibition also affected cell activa- 
tion by single ITAMs, in isolated FcR or TCR subunits. 
Thesame tyrosine-based inhibitory motif (ITIM), which 
is highly conserved in murine and human FcyRllB and 
that was previously shown to inhibit BCR-dependent 
B cell activation, was required to regulate TCR- and 
FcR-dependent cell activation. Our findings endow 
FcyRIIB, and thus IgG antibodies, with general immu- 
noregulatory properties susceptible to act on all ITAM- 
containing receptors. 
Introduction 
An intracytoplasmic consensus activation motif, centered 
on two YxxL sequences separated by 7-12 aa (Reth, 
1989), accounts for the cell-triggering properties of B cell 
receptors for antigen (BCR) (Pleinman et al., 1994) T cell 
receptors for antigen (TCR) (Weiss, 1993) and receptors 
for the Fc portion of immunoglobulins (FcR) (Letourneur 
and Klausner, 1991; Bonnerot et al., 1992; Dabron et al., 
1994). This immunoreceptor tyrosine-based activation 
motif (ITAM) (Cambier, 1995) was found in the intracy- 
toplasmic (IC) domain of the immunoglobulin a (Iga) and 
lg6 subunits of the BCR, in the IC domain of the y, 6, E, 
and csubunitsof theTCR, and in the ICdomain of the FcRy 
subunit, which associates with the IgE-binding a subunit of 
high affinity IgE receptors (FcERI) (Blank, et al., 1989) with 
the IgG-binding a subunits of high-affinity IgG receptors 
(FcyRI) (Scholl and Geha, 1993) and of low affinity IgG 
receptors (FcyRIIIA) (Ra et al., 1989) and with the IgA- 
binding a subunit of high affinity IgA receptors (FcaRI) 
(Pfefferkorn and Yeaman, 1994). It is also present in the 
C-terminal IC domain of the 8 subunit, which associates 
with FcERI and, in mast cells, with FcyRlllA (Kurosaki et 
al., 1992). Finally, it exists in the IC domain of one of the 
single-chain human low affinity IgG receptors (FcyRIIA). 
When aggregated at the cell surface, ITAM-containing 
molecules trigger a cascade of intracellular phosphoryla- 
tions and dephosphorylations, which ultimately result in 
a cellular response (Heldin, 1995). 
FcyRllB are single-chain low affinity receptors for the 
Fc portion of IgG (Hibbs et al., 1986). They have no ITAM 
in their IC domain and, when aggregated at the cell sur- 
face, they do not trigger cell activation (Da&on et al., 1992; 
Latour et al., 1992). Murine (m) and human (h) FcyRllB 
are highly homologous(Brookset al., 1989). Twoisoforms, 
FcyRIIBl and FcyRIIB2, are generated by alternative 
splicing of sequences encoded by the first IC exon of the 
single FcyRllB gene, which differ by a 47 aa or a 19 aa 
insertion in mFcyRIIB1 and hFcyRIIB1, respectively. 
FcyRllB are widely expressed by cells of the lymphoid 
lineage and by cells of the myeloid lineage (Hulett and 
Hogarth, 1994). 
mFcyRllB have long been known to inhibit BCR- 
dependent B cell activation (Sinclair and Chat-r, 1971). 
Multivalent antigen-induced B cell activation is inhibited 
when antigen is complexed to specific IgG antibodies but 
not to F(ab’)* fragments of the same antibodies (Morgan 
and Tempelis, 1978). B cell activation can be triggered by 
anti-immunoglobulin F(ab’)n fragments, but not by anti- 
immunoglobulin IgG antibodies (Sidman and Unanue, 
1979; Phillips and Parker, 1983). This Fc-dependent phe- 
nomenon was demonstrated to involve mFcyRllB (Phillips 
and Parker, 1984) and, more specifically, mFcyRIIB1, 
which are constitutively expressed by mouse B cells (Ami- 
gorena et al., 1989). The molecular analysis of FcyRIIB- 
dependent inhibition of B cell activation established that 
both mFcyRllB isoforms are equally capable of inhibiting 
anti-immunoglobulin-induced B cell activation and that the 
conservation of a 13 aa sequence, in the IC domain of 
mFcyRIIB2, is required for inhibition (Amigorena et al., 
1992; Muta et al., 1994). Finally, hFcyRllB were found to 
exert the same inhibitory effect as mFcyRllB on anti- 
immunoglobulin-induced murine B cell activation (Van den 
Herik-Oudijk et al., 1994). 
We found recently that, when coaggregated to FcERI, 
mFcyRllB inhibit IgEinduced mast cell activation. As a 
result, the release of inflammatory mediators and the syn- 
thesis of cytokines were inhibited. Inhibition required that 
FcERI be coaggregated to mFcyRIIB, whatever the coag- 
gregating ligands; it affected only coaggregated FcERI and 
was reversible upon receptor disengagement. Both 
mFcyRllB1 and mFcyRIIB2 were equally inhibitory, pro- 
vided they had an intact IC domain (Da&on et al., 1995). 
In the present work, we extend to hFcyRllB the regulatory 
properties previously demonstrated for mFcyRIIB, and we 
show that these affect FcERI- as well as hFcyRIIA- 
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Figure 1. Inhibition of FcsRI- and Fc+fIIA- 
Mediated Mast Cell Activation by Human 
FQRllB 
(A) Effect of coaggregating FcERI to FQRII on 
IgE-induced histamine release by human baso- 
phils. The binding of mouse IgE (grey curve) 
and of AT10 F(ab’)* (black curve) to purified 
basophils were assessed by indirect immuno- 
fluorescence with FITC-GAM F(ab’)z. The dot- 
ted curve shows background fluorescence of 
cells incubated with FITC-GAM F(ab’)2 only. 
Relative cell numbers are expressed as a func- 
tion of log 10 fluorescence intensity (insert). 
Cells were sensitized with 0 (open circles), 0.1 
(shaded squares), 0.3 (closed circles), or 1 
(closed squares) @ml mouse IgE, and incu- 
bated with concentrations of AT10 F(abqp indi- 
cated on abscissa before they were challenged 
for serotonin release with GAM F(ab’)*. The 
graph shows the percentage of histamine re- 
leased as a function of the concentration of 
AT1 0 F(ab’)n. 
(6) Inhibition of IgE-induced serotonin release 
by hFcVRllB1 in RBL transfectants. The ex- 
pression of recombinant receptors expressed 
by RBL-2H3 cells transfected with cDNA en- 
coding hFcyRllB1 or hFcyRIIB(IC5) was as- 
sessed by indirect immunofluorescence with 
ATlO(blackcurves)or IV,3(greycu~es)F(ab7~ 
and FITC-GAM F(ab’)*. Dotted curves show 
background fluorescence of cells incubated with FITC-GAM F(ab’), only (inserts). Cells were sensitized with 0 (open circles), 0.1 (shaded squares), 
0.3 (closed circles), or 1 (closed squares) pglml mlgE, and incubated with concentrations of AT10 F(ab’)2 indicated on abscissa before they were 
challenged for serotonin release with GAM F(ab’),. Graphs represent the percentage of serotonin released as a function of the concentration of 
AT1 0 F(abq,. 
(C) Inhibition of hFcyRIIA-mediated serotonin release by hFcyRllB1. RBL transfectants expressing hFcyRllB1 or hFcyRIIB(IC5) were stably re- 
transfected with cDNA encoding hFcyRIIA. The expression of hFqRllA (grey curves) and hFcyRIIA+B (black curves) was assessed by indirect 
immunofluorescence with IV.3 and AT10 F(ab’)n, respectively, as in (B). Transfectants were incubated with indicated concentrations of IV.3 (open 
circles) or AT10 (closed circles) F(ab’)?, and challenged for serotonin release with GAM F(ab$=. Graphs represent the percentage of serotonin 
released as a function of the concentration of IV.3 or AT10 F(ab%. 
dependent mast cell activation. We further extend the reg- 
ulatory properties of mFcyRll6 to TCR-dependent T cell 
activation, we identify the IC domain of the signal- 
transducing ITAM-containing subunits FcRy and TCRI; as 
targetsof inhibition by FcyRIIB, and we show that the same 
tyrosine-based inhibitory motif that was previously shown 
to regulate BCR-dependent B cell activation also regulates 
FcERI- and TCR-dependent cell activation. Our findings 
confer to IgG antibodies a wide array of potential immuno- 
regulatory properties in the immune response. 
Results 
Human FcyRllB Regulate Negatively FcaRI- and 
FcyRIIA-Dependent Mast Cell Activation 
Human peripheral blood basophils express FcsRI, which 
bind both human and murine IgE (Conrad et al., 1983), 
and FqRll (Ishizaka et al., 1979; Anselmino et al., 1989), 
but no FcyRlll (unpublished data). The possibility that 
hFcyRll might regulate negatively IgE-induced reactions 
was examined first on peripheral blood basophils purified 
by elutriation. Cells were acid-eluted to remove human 
IgE bound to FcsRI in vivo and sensitized with various 
concentrations of mouse IgE. Elution of human IgE and 
sensitization by murine IgE was checked by indirect immu- 
nofluorescence. Purified basophils bound the mouse anti- 
hFcyRIIA/B monoclonal antibody (MAb) AT10 (Greenman 
et al., 1991), but they failed to release histamine when 
incubated with AT10 F(ab’)* and challenged with goat anti- 
mouse immunoglobulin (GAM) F(ab$ When sensitized 
with mouse IgE, they released histamine upon challenge 
with GAM F(ab’)*. Histamine release by murine IgE- 
sensitized cells was dose-dependently inhibited if baso- 
phils were preincubated with increasing concentrations of 
AT10 F(ab’)n (Figure 1A). This suggested that hFcyRllB 
might have the same inhibitory properties as mFcyRIIB. 
To confirm this hypothesis, the rat basophilic leukemia 
cell line RBL-2H3, which expresses constitutively FcsRl 
(Barsumian et al., 1981), wasstablytransfected with cDNA 
encoding wild-type hFcyRIIB1 (Warmerdam et al., 1990) 
or hFcyRIIB(lCS), whose 83 aa IC domain was deleted of 
its 58 C-terminal residues. Transfectants bound AT1 0, but 
not the anti-hFcyRIIA MAb IV.3 (Warmerdam et al., 1993) 
F(ab’jn. They released serotonin when sensitized with 
mouse IgE and challenged with GAM F(ab’)*, but not when 
incubated with AT10 F(ab’)r and challenged with GAM 
F(ab’)P. Serotonin release by hFcyRllBl-, but not hFcyRllB- 
(I(X)-expressing transfectants, was inhibited if cells were 
sensitized with IgE and preincubated with AT10 F(ab’)a 
before challenge with GAM F(ab’)n (Figure 1 B). Serotonin 
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release triggered in mast cells by FcsRI aggregation may 
therefore be inhibited when FcsRI are coaggregated to 
hFcyRllB1 with an intact IC domain. 
hFcyRll isoforms expressed by human basophils are 
not known. They react with IV.3 (Anselmino et al., 1989) 
and AT10 (Figure 1 A), but they do not trigger efficient se- 
cretory responses when challenged with IgG immune 
complexes (Van Toorenenbergen and Aalberse, 1981). 
The low numbers of basophils in human peripheral blood 
and the absence of hFcyRIIB-specific antibodies made 
these cells not suitable for the analysis of the respective 
activities of hFcyRllA and hFcyRIIB. We therefore exam- 
ined whether hFcyRllA would trigger RBL cell activation 
and whether hFcyRIIAdependent mast cell activation 
might be inhibited by hFcyRIIB. hFcyRllA are single-chain 
receptors that possess one ITAM in their IC domain and 
they can trigger cell activation (Kolanus et al., 1992; Odin 
etal., 1991). Indeed, hFcyRlIAtriggeredserotonin release, 
when expressed by stable transfection of the correspond- 
ing cDNA into RBL-2H3 cells and aggregated with AT1 0 
F(ab’)? and GAM F(ab’)* (data not shown). To determine 
whether hFcyRIIA-induced cell activation could also be 
regulated negatively by hFcyRIIB, RBL transfectants ex- 
pressing hFcyRllB1 or hFcyRIIB(IC5) were retransfected 
with cDNA encoding hFcyRIIA. Resulting double transfec- 
tants bound ATlO, which recognizes hFcyRllA and 
hFcyRIIB, and IV.3, which recognizes hFcyRllA but not 
hFcyRllB (see Figure 1 B). Both released serotonin when 
hFcyRllA were aggregated by IV.3 F(ab’)* and GAM 
F(ab’)?. A comparable dose-dependent serotonin release 
was induced by coaggregating hFcyRllA to hFcyRIIB(IC5) 
with AT10 F(ab’)? and GAM F(ab’)*. Under the same condi- 
tions, coaggregating hFcyRllA to hFcyRIIB1 triggered a 
weak response that was abolished by increasing concen- 
trations of AT10 F(ab’)* (Figure 1C). Cell activation trig- 
gered by hFcyRllA aggregation may therefore be inhibited 
when hFcyRllA are coaggregated to hFcyRllB1 with an 
intact IC domain. 
Murine FcyRllB Regulate Negatively 
TCR-Dependent T Cell Activation 
Since BCR-and FcRdependent cell activation can be neg- 
atively regulated by FcyRIIB, we examined whether 
FcyRllB might also regulate TCR-dependent cell activa- 
tion. This was first examined in two murine T cell lines 
that express constitutively mFcyRIIB. These were the lym- 
phoma T cell RMA (Ljunggren and Karre, 1985) and the 
anti-pigeon cytochrome C hybridoma T cell 284 (Frank et 
al., 1990). When analyzed by reverse-transcriptase poly- 
merase chain reaction (RT-PCR) with mFcyRIIB-specific 
oligonucleotide primers, both cell lines were found to con- 
tain mFcyRllB1 transcripts, but no mFcyRIIB2 transcripts 
(Figure 2A). When examined by indirect immunofluores- 
cence, both cell lines bound the rat anti-mFcyRIIB MAb 
2.4G2 (Unkeless, 1979) and the hamster anti-mCD3s MAb 
2Cll (Leo et al., 1987) (Figure 28). When incubated with 
2Cll F(ab’)n and challenged with GAM F(ab’)n coated to 
plastic, both cell lines released interleukin 2 (IL-2). IL-2 
production was dose-dependently inhibited when the cells 
were incubated with 2Cll F(ab’)n and increasing concen- 
284 RMA 
C -ml 1 
2.4G2 F(ab’)P @g/ml) 
Figure 2. Effect of Coaggregating CD3s and mFcyRllB1 on IL-2 Secre- 
tion by T Cell Lymphoma and Hybridoma Cells 
(A) mFcyRllB transcripts in 284 and RMA cells. The presence of 
mFcyRllB transcripts was examined by RT-PCR in total RNA ex- 
tracted from 284 and RMA cells. RNA extracted from BW5147-SC cells 
transfected with mFcyRllB1 or mFcyRllB2 cDNA (see Figure 3) was 
used as positive controls. Oligonucleotide primers used hybridized, 
on the one hand, with the last 10 nt of the second extracellular exon 
and the 20 first nt of the transmembrane exon and, on the other hand, 
with the last 33 nt of the third IC exon of the mFc-rRllB gene, respec- 
tively. The predicted sizes of amplified sequences were 409 bp for 
mFcyRllB1 and 259 bp for mFcrRIIB2. PCR products were analyzed 
by electrophoresis in 1.5% agarose gel. 
(B) Expression of mFcyRllB by 284 and RMA cells. Cells were exam- 
ined by indirect immunofluorescence with 2.4G2 (black curve) or 2Cll 
(grey curve) and FITC-GAM F(ab’)*. Dotted curves show background 
fluorescence of cells incubated with FITC-GAM F(ab?l only. 
(C) IL-2 secretion by 284 and RMA cells upon coaggregation of CD3s 
and mFcrRIIB. Cells were incubated with 0 (open circles), 0.3 (shaded 
triangles), or 3 (closed triangles) pg/ml2Ci 1 F(abq2 and concentrations 
of 2.4G2 F(ab’)* indicated on abscissa, before they were challenged 
by being incubated in GAM F(ab’)n-coated plates for 12 hr at 37%. 
IL-2 released in supernatants was assayed for PH]thymidine incorpora- 
tion in CTLL-2 cells. Graphs represent the number of cpm incorporated 
in CTLL-2 cells as a function of the concentration of 2.462 F(ab’)z. 
trations of 2.462 F(ab’)* before challenge (Figure 2C). This 
inhibition suggested that the coaggregation of TCR to 
mFcyRllB might inhibit T cell activation triggered by TCR 
aggregation. 
To ascertain the inhibitory effect of mFcyRllB on TCR- 
dependent T cell activation, mouse lymphoma T cells 
BW5147, which do not express mFcyRllB (Da&on et al., 
1985) and whose TCR had been reconstituted with TCRG 
and TCR< (Wegener et al., 1992), were stably transfected 
with cDNA encoding wild-type mFcyRIIB1 or mFcyRIIB2, 
or mFcyRIIB(ICl), whose IC domain was deleted of all but 
1 aa (Miettinen et al., 1989). Transfectants bound 2Cll 
and 2.4G2 F(abqn. When plated on dishes coated with 
2Cll F(ab’)*, transfectants produced IL-2. IL-2 production 
by mFcyRIIBl- and mFcyRIIB2-expressing transfectants 
was dose-dependently inhibited if dishes were coated with 
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Figure 3. Inhibition of TCR-Mediated T Cell Ac- 
tivation by mFcyRllB 
TheexpressionofCD3sandmFc+fllBbyTCR- 
mFqflIIB(IC1) 
reconstituted lymphoma T cells BW5147-65, 
transfected with cDNA encoding mFcyRllB1, 
mFcyRIIB2, or mFcyRIIB(IC1) was assessed 
by indirect immunofluorescence with 2Cll 
F(ab’)* (grey curves) or 2.4G2 F(ab’k (black 
curves), and FITC-GAM F(ab’)p. Dotted curves 
show background fluorescence of cells incu- 
bated with FITC-GAM F(ab), only (inserts). 
Cells were plated in dishes coated with 0 (open 
circles), 6 (shaded squares), 12 (closed trian- 
gles), 25 (closed circles) or 50 (closed squares) 
uglml 2Cll F(ab’k and concentrations of 
2.4G2 F(ab’)2 indicated on abscissa. IL-2 in 12 hr culture supernatants was assayed for [3H]thymidine incorporation in CTLL-2 cells. Graphs represent 
cpm incorporated in CTLL-2 cells as a function of the concentration of 2.4G2 F(ab’h. 
2Cll and increasing concentrations of 2.4G2 F(ab’)* (Fig- 
ure 3). Under the same conditions, IL-2 production by 
mF~RIIB(ICl)-expressing cells was not inhibited but 
rather enhanced, possibly because TCR aggregation was 
increased. IL-2 production triggered in T cells by TCR ag- 
gregation may therefore be inhibited when TCR is coag- 
gregated to mFcyRIIB1 or to mFcyRIIB2 with an intact IC 
domain. 
Murine FcyRllB Regulate Negatively ITAM-Dependent 
Cell Activation 
mFcyRllB was reported to inhibit lymphoma B cell activa- 
tion induced by chimeric molecules having the IC domain 
of the BCR Iga subunit (Muta et al., 1994). We therefore 
examined whether mFcyRllB might inhibit serotonin re- 
lease triggered in RBL cells by single-chain chimeras hav- 
ing the IC domain of the signal-transducing subunit FcRr 
(Letourneur and Klausner, 1991; Da&on et al., 1992; La- 
tour et al., 1992). To test this hypothesis, RBL cells were 
cotransfected with cDNA encoding mFcrRllB and with 
cDNA encoding chimeras having the extracellular and 
transmembrane domains of the hlL-2 receptor a chain 
(bearing the Tat epitope) and the IC domain of FcRy (Tacy) 
(Letourneur and Klausner, 1991). Transfectants bound 
2.4G2 and anti-Tat 7G7 (Rubin et al., 1985) F(ab$. They 
released serotonin when incubated with 7G7 F(ab$ and 
challenged with GAM F(ab’)n. Anti-Tat-induced serotonin 
release was inhibited when Tacy chimeras were coaggre- 
gated to mFcyRllB (Figure 4A). The IC domain of FcRy, 
which is sufficient for triggering cell activation upon aggre- 
gation, is also a sufficient target for FcyRIIB-dependent 
inhibition. This suggests that all multichain FcRs that 
share this subunit are susceptible to be regulated by 
Fc+rRIIB. 
This result led us to examine whether FcyRllB would 
inhibit cell activation by isolated TCR transduction sub- 
units. The TCR contains two signal-transducing modules, 
CD3s and TCRI;, each of which is sufficient to trigger T 
cell activation (Wegener et al., 1992). RBL-2H3 cells were 
therefore stably transfected with cDNAs encoding chime- 
ric molecules having theextracellular and transmembrane 
domainsof the hlL-2Ra subunit and the IC domain of either 
CD~E (Tats) or TCRC (TacQ (Letourneur and Klausner, 
1991). Transfectants were also generated, which ex- 
pressed Tacl; whose IC domain was reduced to the first 42 
aa of TCRC, that contain the first TCRE ITAM (Tac?JlC42]). 
When aggregated by anti-Tat 7G7 F(ab’)* and GAM 
F(ab%, Tacl; and Tacl;(lC42) triggered serotonin release, 
but Tats did not (data not shown). RBL transfectants ex- 
pressing mFcyRllB2 or mFcyRIIB(IC1) were therefore re- 
transfected with cDNAs encoding Tact or Tacc(lC42). 
Double transfectants were examined for the expression 
of Tat chimeras and mFcyRllB by indirect immunofluores- 
cence, with 7G7 and 2.462, respectively, and for serotonin 
release upon challenge with GAM F(ab’)n, after incubation 
with 7G7 F(ab’), in the presence of increasing concentra- 
tions of 2.4G2 F(ab’)*. Serotonin release triggered by the 
aggregation of Tacl; (Figure 48) or Tacl;(lC42) (Figure 4C) 
was dose-dependently inhibited when these were coag- 
gregated to mFcyRIIB2, but not to mFcyRIIB(IC1). Chime- 
ras containing one or three ITAMS are therefore targets 
for inhibition by mFcyRllB with an intact IC domain. 
The Same FcyRllB Motif, which Regulates Negatively 
BCR-Dependent B Cell Activation, also Regulates 
Negatively FczRI- and TCR<-Dependent 
Cell Activation 
We found previously that mFcyRIIB-dependent inhibition 
of IgEinduced mast cell activation requires specific IC 
sequences common to mFcyRIIB1 or mFcyRIIB2 as both 
FcyRllB isoforms were equally inhibitory, whereas 
mFcyRllB lacking IC domain or chimeric receptors made 
with the extracellular and transmembrane domains of 
mFcyRllB and the IC domain of the mFcyRllla subunit 
were not (Da&on et al., 1995). To identify inhibitory se- 
quences, mFcyRIIB2(ICSl) and mFcyRIIB2(lC18), gener- 
ated by deleting the 16 or the 29 C-terminal amino acids 
of mFcyRIIB2, respectively, were used. mFcyRllB2(A43) 
and mFcyRIIB2(G26) were also generated, by changing 
Tyr43 or Tyr26 into Ala and Gly, respectively (Figure 5A). 
Mutated mFcyRllB were expressed in RBL-2H3 cells. Re- 
sulting transfectants were sensitized with rat IgE and incu- 
bated with or without 2.462 F(ab’)n fragments before they 
were challenged with mouse anti-rat immunoglobulin 
(MAR) F(ab$. When coaggregated to FcsRI, mFcy- 
RllB2(IC31) and mFcyRllB2(A43) inhibited IgE-induced 
serotonin release, but not mFcyRllB2(IC18) or mFcy- 
RllB2(G26) (Figure 58). Amino acids 19-31, which were 
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Tat-t; + mFcpllB2 Tat-t; + mFcyRIIB(IC1) 
Tat-fJlC42) + mFcyRIIB2 Tat-c(lC42) + mFcyRIIB(IC1) 
50. 
2.4G2 F(ab’)2 (f.rg/ml) 
Figure 4. Inhibition of Tacy-, Tacr-, and Ta&,(lC42)-Mediated Serotonin 
Release by mFcyRllB 
(A) Inhibition of Tacy-mediated serotonin release by mFcrRIIB. cDNAs 
encoding mFcyRllB1 and Tacy were cotransfected in RBL-2H3 cells. 
The expression of recombinant molecules was assessed by indirect 
immunofluorescence with 2.4G2 F(abqn (black curve) or 767 F(ab?2 
(grey curve) and FITC-GAM F(ab’b. The dotted curve shows back- 
ground fluorescence of cells incubated with FITC-GAM F(abql only 
(insert). Cells were incubated with 0 (open circles), 0.3 (closed circles), 
or 1 (closed squares) uglml 7G7 F(ab’k and concentrations of 2.462 
F(ab’)* indicated on abscissa, before they were challenged for seroto- 
nin release with GAM F(ab),. 
(Band C) Inhibition of Tact- or TacrJlC42)-mediated serotonin release 
by mFcyRIIB. The expression of recombinant molecules expressed 
by RBL-2H3 cells transfected with cDNAs encoding mFcyRllB2 or 
mF~RIIB(IC1) and Taci(B) orTacc(lC42) (C) was assessed by indirect 
immunofluorescence with 2.4G2 F(ab)? (black curves) or 7G7 F(ab’k 
(grey curves) and FITC-GAM F(ab’b. Dotted curves show background 
reported to inhibit B cell activation (Amigorenaet al., 1992; 
Muta et al., 1994), are therefore also required for inhibiting 
IgE-induced mast cell activation. Among these amino 
acids, Tyr26 is essential for inhibition. 
mFcyRllB residues critical for inhibition are highly con- 
served in hFcyRllB (Figure 6A). To identify inhibitory se- 
quences in hFcyFlIIB, RBL cells were transfected with 
cDNAs encoding wild-type or IC-deleted hFcyRIIB2. Nei- 
ther wild-type hFcyRllB2 nor hFcyRllB2 deletants trig- 
gered serotonin release upon aggregation by AT1 0 F(ab’)* 
and GAM F(ab%. When coaggregated to FcsRI, hFcyRIIB2 
inhibited IgE-induced serotonin release. hFcyRllB2(IC34), 
in which the 12 C-terminal amino acids were deleted, also 
inhibited IgEinduced serotonin release, but not hFcyRII- 
B2(IC21), in which the 25 C-terminal amino acids were 
deleted (Figure 6B). This confirms the importance of resi- 
dues identified as critical in mFcyRIIB2. 
To determine which sequences inhibit TCRGdependent 
cell activation, RBL transfectants expressing mFcyRIIB2 
mutants were stably retransfected with cDNAs encoding 
Tacr, and serotonin release was examined when coag- 
gregating Tat< to mutated mFcyRIIB2. Coaggregating 
Tacl; to mFcyRIIB2(lC31) or to mFcrRllB2(A43), but not 
to mFclRIIB2(lC16) or to mFcyRIlB2(G26), inhibited anti- 
Tat-induced serotonin release (Figure 7). The same tyro- 
sine-containingsequence thereforeaccountsforthe nega- 
tive regulation of cell activation by FcERI and by TCRI;. 
From a 13 aa FcyRllB Inhibitory Sequence towards 
the Definition of an lmmunoreceptor 
Tyrosine-Based Inhibition Motif (ITIM) 
A 13 aa sequence, common to mFcyRIIB1 and 
mFcyRIIB2, was first reported to inhibit BCR-dependent 
B cell activation (Amigorena et al., 1992). This conclusion 
was based on the analysis of the inhibitory properties of 
mFc-rRllB mutants bearing intracytoplasmic deletions of 
increasing length expressed in the FcyR-negative variant 
of the A20/2J murine lymphoma cell line, llA1.6. A con- 
struction containing the same 13 aa, excised from the 
mFcyRllB IC domain and placed C-terminal to the first 16 
aa of the TCRC IC domain, also inhibited anti-immu- 
noglobulin-induced IIA1.6 cell activation (Muta et al., 
1994). The tyrosine residue contained in this sequence, 
at position 26 in the IC domain of mFcyRIIB2, was critical 
for inhibition. We found in the present work that, when 
expressed in RBL-2H3 cells, the same 13 residues were 
also required for mFcyRllB to inhibit FcsRCmediated or 
TCR<-mediated serotonin release, and that the conserva- 
tion of Tyr26 was mandatory for inhibition of responses 
fluorescence of cells incubated with FITC-GAM F(ab’)* only (inserts). 
Cells were incubated with 0 (open circles), 0.1 (shaded squares), 0.3 
(closed circles), or 1 (closed squares) &ml 7G7 F(aba and concentra- 
tions of 2.4G2 F(ab’k indicated on abscissa, before they were chal- 
lenged for serotonin release with GAM F(ab’b. Graphs represent the 
percentage of serotonin released as a function of the concentration 
of 2.4G2 F(ab’)*. 
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Figure 5. Mapping of Murine FqRllB2 IC Sequences Required for Inhibition of FceRI-Mediated Mast Cell Activation 
(A) Structure of mutant mFcyRllB expressed in RBL cells. Only transmembrane (TM) and intracytoplasmic domains are shown. Identical patterns 
correspond to identical amino acid sequences. lntracytoplasmic amino acids were numbered, giving number 1 to the first N-terminal IC residue. 
(B) Expression of mutant mFcyRllB and inhibition of IgE-induced serotonin release by RBL transfectants. The expression of recombinant receptors 
by RBL-2H3 cells was examined by indirect immunofluorescence with 2.4G2 and FITC-labeled MAR F(ab’)n. Dotted curves show background 
fluorescence of cells incubated with FITC-MAR F(ab$ only (inserts). Cells were sensitized with 0 (open circles), 0.1 (closed circles), or 0.3 (closed 
squares) pglml rat IgE LO-DNP-30 and with concentrations of 2.4G2 F(ab’J2 indicated on abscissa, before they were challenged for serotonin 
release with MAR F(abqz. Graphs represent the percentage of serotonin released as a function of the concentration of 2.462 F(abh. 
““I 
hFcrWlB2 50 
1 
hFcyRll62(lC34) 80 hFcyRllB2(lC21) 
* 1 
AT1 0 F(ab’)2 (pg/ml) 
Figure 6. Mapping of Human FcyRllBP IC Sequences Required for Inhibition of FceRI-Mediated Mast Cell Activation 
(A) Comparison of amino acid sequences of mFcyRllB2 and hFqRllB2 IC domains. Arrows indicate where translation was arrested by introducing 
stop codons in corresponding cDNAs. 
(B) Inhibition of IgE-induced serotonin releasa by wild-type and IC deleted hFcyRllB2 in RBL transfectants. The expression of recombinant receptors 
expressed by RBL-2H3 cells transfected with cDNA encoding hFcyRIIB2, hFcyRllB2(IC34), and hFcyRIIB2(lCPl) was assessed by indirect immuno- 
fluorescence with AT10 F(ab’)* and FITC-GAM F(abvn. Dotted curves show background fluorescence of cells incubated with FITC-GAM F(ab’)* 
only (inserts). Cells were sensitized with 0 (open circles), 0.01 (closed triangles), 0.03 (closed circles), or 0.1 (closed squares) pg/ml mlgE, and 
incubated with concentrations of AT10 F(abvn indicated on abscissa before they were challenged for serotonin release with GAM F(ab’)*. Graphs 
represent the percentage of serotonin released as a function of the concentration of AT10 F(ab’),. 
Regulation of ITAM-Dependent Cell Activation by FcyRllB 
641 
Figure 7. Mapping of Murine Fr~rRllB2 IC Se- 
quences Required for Inhibition of Tacr- 
Mediated Mast Cell Activation 
TX-< + mFc$WBP(IC31) Tat-< + mFcyRIIBP(IC18) Tat-C + mFcpllB2(A43) Tat-< + mFc-,NlB2(G26) 
rl;;I iz & ;p, 
The expression of recombinant molecules ex- 
pressed by RBL transfectants expressing 
mFcyRIIB2, mFcyRIIBP(IC31), mFcrRIIBP- 
(ICIS), mFcyRllB2(A43), or mFcrRIIB2(G26) 
and retransfected with cDNA encoding TacC 
was assessed by indirect immunofluorescence 
with 2.4G2 F(aby2 (black curves) or 767 F(ab’), 
- 
0 10’ 100 10’ 0 10 ’ 100 !(I’ 0 10 ’ 100 (0’ 0 10’ 100 <(I’ (grey curves) and FITC-GAM F@I)~. Dotted 
2.4G2 F(ab’)Z (&ml) curves show background fluorescence of cells 
incubated with FITC-GAM F(ab’h only (in- 
serts). Cellswere incubated with 0 (open circles), 0.1 (shaded squares), 0.3 (closed circles), or 1 (closed squares) uglml7G7 F(ab’h and concentrations 
of 2.4G2 Flab% indicated on abscissa. before thev were challenaed for serotonin release with GAM F(ab’)n. Graphs represent the percentage of 
serotonin released as a function of the concentration of 2.462 F(ab’)n. 
triggered by both receptors. Sequences that inhibit BCR- 
mediated B cell activation are therefore the same as those 
that inhibit FcsRI-mediated and TCRC-mediated mast cell 
activation. 
We report here that IgE-induced serotonin release was 
also inhibited when RBL FcERI were coaggregated to 
hFcyRIIB. hFcrRIIB1 and hFcyRllB2 were equally inhibi- 
tory and RBL transfectants expressing hFcrRllB with 
C-terminal deletions demonstrated that a 13 aa sequence 
containing 11 of the 13 murine residues is necessary for 
inhibition. hFcyRllBare homologoustomFcyRllBand they 
share a number of IC residues. Interestingly, amino acids 
in the inhibitory sequence are conserved more than any- 
where else in the receptor. Conserved residues help to 
define an inhibitory motif whose provisional sequence is 
AENTlTYSLLxH and in which hallmark residues will be 
identified when more regulatory molecules are described. 
One may notice the YxxL sequence in this motif. If phos- 
phorylated, it would make FcyRllB a possible ligand for 
SH2 domains of protein tyrosine kinases and phospha- 
tases. When coaggregated to BCR, mFcyRllB were re- 
cently shown to become tyrosine-phosphorylated and to 
associate to the SH2 domains of the protein tyrosine phos- 
phatase PTPl C (D’Ambrosio et al., 1995). Interestingly, 
a YxxllL sequence is also found, with an inverse orienta- 
tion, in molecules belonging to the C-type lectin family. 
These include the human low affinity IgE receptor FcsRlla 
and the mast cell-associated function antigen (MAFA). 
MAFA (Guthmann et al., 1995) and hFcsRll (Luo et al., 
1991) were reported to inhibit FcsRI-dependent mast cell 
activation and BCR-dependent B cell activation, respec- 
tively. This further supports the concept of a YxxL-based 
inhibitory motif. The structural analogy with ITAMs and 
the requirement for the tyr residue for inhibition justify that 
this motif be designated ITIM. 
From the Inhibition of BCR-Dependent B Cell 
Activation by FcyRllB to the Negative Regulation 
ITAM-Dependent Cell Activation by ITIM 
Inhibition was for long a unique property of mFcyRIIB, 
restricted to BCR-dependent activation of murine B cells. 
It was recently extended to hFcyRllB (Van den Herik- 
Oudijk et al., 1994). Inhibition, however, was observed in 
murine IIA1.6 cells, and evidence that the activation of 
human B cells may be controlled by hFcrRllB remains to 
be obtained. FcR-dependent mast cell activation, BCR- 
dependent B cell activation, and TCR-dependent T cell 
activation all involve ITAMs and protein tyrosine kinases 
of the same families. FcR, BCR, and TCR, however, have 
specific ITAMs and ITAM combinations, they involve nei- 
ther the same signal transduction sequence of events, nor 
the same tyrosine kinases and they function in different 
intracellular environments in B cells, T cells, and mast 
cells. We found previously that mFcyRllB can regulate 
FcsRf-mediated mast cell activation, in both BMMC and 
in RBL cells (Da&on et al., 1995) and we show here that 
hFcyRllB can regulate FcsFlI-mediated cell activation not 
only in RBL cells, but also in human peripheral blood baso- 
phils. In addition, we found that hFcyRllB can negatively 
regulate hFcyRIIA-mediated mast cell activation. Finally, 
we further extend mFcyRIIB-dependent regulation of cell 
activation to TCR. This was seen when coaggregating the 
TCR to mFcyRllB1 expressed constitutively by the lym- 
phoma T cell RMA and by the hybridoma T cell 284, or 
when coaggregating a reconstituted TCR to mFcyRllB1 
or mFcyRllB2 transfected in BW5147 lymphoma T cells. 
FcyRIIB-dependent inhibition of cell activation is restricted 
neither to BCR nor to B cells. It is susceptible to regulate 
negatively cell activation triggered by ITAM-containing re- 
ceptors, irrespectively of the cell type. This suggests that 
regulation affects cell activation pathways that are com- 
mon to ITAM-containing receptors. 
Supporting this hypothesis, ITAM-containing subunits 
of multichain receptors were found to be a target for inhibi- 
tion. We report here that, like cell activation triggered by 
chimeras having the IC domain of the Iga subunit of the 
BCR (Muta et al., 1994) cell activation triggered by chime- 
ras having the IC domain of FcRy or of TCRZ was inhibited 
when coaggregating chimeras to FcyRIIB. Inhibition could 
be further focused on ITAM% as a comparable inhibition 
of cell activation was observed when mFcy RIIB were coag- 
gregated to chimeras having the whole TCRC IC domain 
or an IC domain reduced to the one ITAM-containing first 
42 aa. The aggregation of chimeras having the IC domain 
of lgp (Choquet et al., 1994) or FIXRIP (Jouvin et al., 1994) 
failed to trigger a cytokine response in B cells or mediator 
release in mast cells, respectively, and we failed to trigger 
a secretory response of RBL cells by aggregating CD~E 
(the latter chimera, however, triggered IL-2 production in 
T cells; Letourneur and Klausner, 1992). Whether these 
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Table 1. Cells whose Activation May Be Negatively Regulated 
by ITIM 
Activating 
Receptors Murine cells Human cells 
BCR 
FcERI 
FcyRI 
FcyRlllA 
FcaRl 
Fr.qRllA 
TCR 
0 cells 
Mast cells 
Macrophages 
Monocytes 
Neutrophils 
Mast cells 
Macrophages 
Langerhans cells 
T cells 
I3 cells 
Basophils 
Mast cells 
Langerhans cells 
Activated monocytes 
Activated eosinophils 
Macrophages 
Monocytes 
Macrophages 
Activated monocytes 
Macrophages 
Monocytes 
Eosinophils 
B cells 
Macrophages 
Monocytes 
Basophils 
Some T cells 
Murine 8 cells, murine mast cells, murine T cells, and human basophils 
were shown to be subjected to FqRllB IT&f-dependent negative regu- 
lation. Other cells are potentially regulated as they are activated via 
ITAM-containing receptors and express FcyRIIB. 
ITAM-containing subunits may be targets of the inhibition 
was therefore not investigated. 
If, as we found it, TCRI; and FcRy are sufficient targets 
for FcyRIIB-dependent inhibition, one may anticipate that 
the same regulation be extended to other receptors associ- 
ated with these subunits. FcyRllB may regulate equally 
well TCR-dependent cell activation in T cells that express 
a TCRaP or a TCRyG in association with TCRC or in associ- 
ation with FcRr (Kurosaki et al., 1991). FcRy associates 
to the ligand-binding a subunit of FcERI, FcyRI, FcyRIIIA, 
and FcaRI. FcyRllB may therefore regulate various IgE-, 
IgG-, and IgA-induced responses provided cellscoexpress 
FcyRllB and corresponding receptors. With the notable 
exception of natural killer cells, which express FcyRlllA in 
the absence of FqRIIB, these include, in mice, mast cells, 
macrophages, monocytes, and Langerhans cells, and in 
humans, macrophages and monocytes, Langerhans cells, 
polymorphonuclear neutrophils, basophils, and eosino- 
phils (Table 1). Cell activation-triggering FcR and cell acti- 
vation-regulating FcR that are coexpressed on a single 
cell function as the subunits of multichain receptors. The 
constitution of such multichain receptor complexes de- 
pends on the cell type, on cytokines which differentially 
regulate the various FcR, and on the composition of im- 
mune complexes with which they interact. Resulting re- 
ceptor complexes with variable compositions will trans- 
duce variable signals to cells whose biological responses 
may be finely tuned by environmental factors. 
From a Feedback Control of IgG Production to a 
General lmmunoregulatory Role 
of IgG Antibodies 
As long as it was restricted to B cells, regulation of BCR- 
triggered cell activation by FwRllB was viewed as a nega- 
tive feedback mechanism. Once synthesized by plasma 
cells, IgG antibodies could become complexed to specif- 
ic antigens. Immune complexes would bind to low affinity 
FcyR and trigger a variety of biological responses. They 
would bind also to specific BCRs via the antigen moiety 
of immune complexes and to B cell FcyRIIBl via Fc por- 
tions. As a result of the coaggregation of BCR to FcyRIIB, 
the negative regulation of B cell activation would ultimately 
result in decreasing specifically the antibody response to 
that antigen. This mechanism probably accounts for the 
isotype-specific feedback effects of antibodies on an in 
vitro antibody response first described by Henry and Jerne 
(1968). By extending FcyRIIB-induced regulation of cell 
activation to other ITAMcontaining receptors, our work 
enables to understand the phenomenon from a different 
perspective. If FcyRllB negatively regulate ITAM-depen- 
dent activation of cells of the lymphoid and myeloid lin- 
eages, they endow IgG antibodies with a general immuno- 
regulatory role. The potential biological consequences are 
several. 
One concerns allergic reactions. Allergic reactions are 
initiated by the aggregation of FcsRI-bound IgE by multiva- 
lent antigens on the membrane of mast cells and baso- 
phils. IgE antibodies, however, are not produced alone 
during an immune response, but together with antibodies 
of other classes (Snapper and Mond, 1993). When antigen 
reaches IgE-sensitized mast cells, it is therefore probably 
complexed to IgG antibodies. Since mast cells (Benhamou 
et al., 1990) and basophils (Anselmino et al., 1989) coex- 
press FcERI and FcyRIIB, these receptors are coaggre- 
gated by immune complexes at the cell surface. Our re- 
sults suggest that, under physiological conditions, 
IgE-induced reactions may be controlled by IgG, so that 
no sign of hypersensitivity appears in normal individuals. 
We indeed showed that mast cell FcsRI and FcyRllBl 
could be efficiently coaggregated by the Fc portion of IgE 
and IgG antibodies to distinct epitopes of the same antigen 
(Da&on et al., 1995). The confirmation that inhibition func- 
tions in human peripheral blood basophils provides a likely 
mechanism to the beneficial effects of desensitization of 
allergic patients. Reduced allergic symptoms are in gen- 
eral correlated with a high titer of specific IgG antibodies 
induced by the repeated injections of allergen (Gleich et 
al., 1978). The finding that hFcyRIIA-dependent mast cell 
activation is inhibited by the coaggregation to hFc+yRllB 
explains that IgG immune complexes are usually unable 
to trigger basophils to release histamine (Van Toorenen- 
bergen and Aalberse, 1981). Human basophils probably 
express hFcyRIIA, since they bind hFcyRllA-specific IV.3 
antibodies (Warmerdam et al., 1993; Anselmino et al., 
1989), and by RT-PCR with hFcyRIIA- and hFcyRIIB- 
specific primers, the human basophil-like cells KU812 
were found to contain hFcrRllA and hFcyRllB transcripts. 
KU812 cells released histamine in response to ionomycin, 
but not in response to FcyRll aggregation (data not 
shown). Other biological consequences concern the vari- 
ety of T cell-dependent immune responses. The regula- 
tion of TCR-dependent cell activation by FcyRllB suggests 
that IgG antibodies against surface mGleCUleS of major 
histocompatibility complex-associated peptide-bearing 
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cells might regulate T cell activation. This could affect T 
cell functions, both at the initiation of immune responses, 
by down-regulating antigen presentation to Th cells, and 
at the effector level, by down-regulating cell-mediated im- 
munity such as the cytotoxic activity of CTL. Alloantigen- 
activated T cells do express FcyRllB (Leclerc et al., 1977), 
which might regulate cytotoxicity of CTL on IgG-coated 
target cells. This might occur in viral infections that induce 
IgG antibodies to viral epitopes expressed by infected 
cells. Supporting this hypothesis, the growth of allogeneic 
tumor or normal tissues can be enhanced in vivo by in- 
jecting IgG antibodies against antigens borne by grafted 
cells (Kaliss, 1956). This enhancement phenomenon was 
described to be isotype-specific (Irvin et al., 1967; Voisin 
et al., 1966) and to depend on the Fc portion of antibodies 
(Cape1 et al., 1979). 
Experimental Procedures 
Antibodies and Antibody Fragments 
The rat IgE MAb LO-DNP-30 was from IMEX (Universite de Louvain, 
Bruxelles, Belgium). The mouse IgE MAb 2662-l was purifie from 
culture supernatant of a subclone of DNP-Hi-s-26 hybridom $ cells 
(Liu et al., 1960). The rat anti-mFcyRIIB 2.462 MAb (Unkeless, 1979) 
was purified by affinity-chromatography on protein G-sepharose from 
ascitic fluid of nude mice inoculated with 2.462 hybridoma cells intra- 
peritoneally. The mouse anti-hFcyRIIA MAb IV.3 (Looney et al., 1966) 
the mouse anti-hFcrRIIA/B MAb AT10 (Greenman et al., 1991) the 
mouse anti-Tat MAb 7G7 (Rubin et al., 1965) and the hamster anti- 
mCD3sMAb2Cll (Leoetal., 1967) werepurifiedfrom culturesuperna- 
tant by affinity chromatography on protein G-sepharose. F(ab’k frag- 
ments were obtained by pepsin digestion for 46 hr. The purity of IgG 
and F(ab’h fragments was assessed by SDS-PAGE analysis. Unla- 
beled and fluorescein isothiocyanate (FITC)-labeled MAR F(ab’j2 frag- 
ments, as well as GAM F(ab’)* fragments were from Jackson Immuno- 
research Laboratories (West Grove, Pennsylvania) 
Cells 
RBL-2H3 cells (Barsumian et al., 1961) were cultured in DMEM supple- 
mented with 10% fetal calf serum (FCS), 100 IUlml penicillin, and 100 
uglml streptomycin. Only adherent RBL cells, recovered with trypsin- 
EDTA, were used. RMA cells (Ljunggren and Karre. 1965) were cul- 
tured in RPM1 supplemented with 10% FCS, 100 IUlml penicillin, and 
100 Kg/ml streptomycin. 284 cells (Frank et al., 1990) were cultured 
in RPM1 supplemented with 10% FCS, 1 uM P-mercaptoethanol, 2 mM 
sodium pyruvate, 100 IUlml penicillin, and 100 pglml streptomycin. 
BW5147-6C cells (Wegener et al., 1992) were cultured in DMEM sup- 
plemented with 10% FCS, 1 uM P-mercaptoethanol, 100 IUlml penicil- 
lin, and 100 us/ml streptomycin. CTLL-2 cells were cultured in RPM1 
supplemented with 10% FCS, 1 uM 2-mercaptoethanol, 2 mM sodium 
pyruvate, 100 IUlml penicillin, 100 uglml streptomycin, and 24 hr su- 
pernatant from 5 uglml concanavalin A-activated (BALE/c x CBA)Fl 
spleen cells diluted 11100. All culture reagents were from GIBCO BRL 
(Paisley, Scotland), except RPM1 medium, purchased from Seromed 
(Biochrom KG, Berlin, Germany). Basophils were purified byelutriation 
from buffy coat from a blood donor and acid eluted as described (Pas- 
mans et al., 1994). 
cDNA Constructlons and Transfectants 
RBL-2H3 cells stably transfected with cDNAs encoding mFcyRIIB1. 
mFcyRIIB2, mFcyRIIB(ICl), mFcyRIIBS(IC16), mF~RllB2(IC31), 
mFcTRllB2(G26), and mFcyRllB2(A43) were described previously 
(Da&on et al., 1993). cDNAs encoding hFcyRIIB1, hFcrRllB2 (Warm- 
erdam etal., 1990) and hFcrRIIB(IC5) generated by introducing astop 
codon 3’to nucleotides coding for the fifth intracytoplasmic residue in 
cDNA encoding hFcrRIIB2, were inserted into an expression vector 
under the control of the SRa promoter in pBR322 (Takebe et al., 1968) 
and in which a resistance gene to zeocin was introduced (NT-zeo). 
cDNAs encoding hFcyRIIBP(IC21) and hFcyRllB2(IC34) were gener- 
ated by introducing a stop codon 3’ to nucleotides coding respectively 
for the twenty-first and the thirty-fourth intracytoplasmic residue in 
cDNA encoding hFcyRIIB2, and inserted into the NT vector in which 
a resistance gene to neomycin was introduced (NT-neo). The cDNAs 
encoding wild-type and mutated hFcyRllB were linearized and stably 
transfected into REL-2H3 cells by electroporation. Transfectants were 
selected by culture with 500 @ml zeocin (Cayla, Toulouse, France) 
or250 pglml geneticin (GIBCO BRL). cDNAencoding hFc-rRllA(Hibbs 
et al., 1966) inserted in NT-neo, was linearized and stably transfected 
into hFcrRIIBl- or hF~RIIB(IC5)expressing RBL transfectants. Trans- 
fectants were selected by culture with 250 uglml geneticin. cDNAs 
encoding mFcyRllB1, mFcyRIIB2, or mFc-rRIIB(ICl), inserted in NT- 
zeo, were linearized and stably transfected into BW5147-5& cells, un- 
der the same conditions as for RBL cells. Transfectants were selected 
by culture with 500 uglml zeocin. cDNA encoding Tacy, in pBR322, 
wascotransfected into RBL-2H3 cellswith cDNA encoding mFr?rRIIBl, 
in a pRC-CMV vector containing a neomycin resistance gene. 
Transfectantswere selected by culture with 250 uglml geneticin. cDNA 
encoding TacL(lC42) was generated by introducing a stop codon, 3’ 
to nucleotides coding for the forty-second intracytoplasmic residue in 
cDNA encoding Tacr (16). cDNA encoding Tacr was inserted in NT- 
zeo, linearized, and stably transfected into RBL transfectants express- 
ing mFcyRllB1, mFcyRIIB2, mFcyRIIB(ICl), mFcyRIIB(ICSl), mFcrRI- 
lB(lCl6), mFcyRllB2(A43), or mFcrRIIB(G26). Transfectants were se- 
lected by culture with 500 pglml zeocin. cDNA encoding Tacc(lC42) 
was inserted in the NTvector in which a resistance gene to hygromycin 
was introduced, linearized, and stably transfected into RBL transfec- 
tants expressing mFcyRIIB1 or mFc-rRIIB(ICl). Transfectants were 
selected by culture with 1 mglml hygromycin (Boehringer-Mannheim, 
Germany). The sequence of all cDNAs modified by PCR was deter- 
mined on the two strands by dideoxynucleotide sequencing before 
transfection. RBL transfectants recovered after selection were cloned 
with steel cylinders as described (Da&on et al., 1992). BW5147 
transfectants recovered after selection were cloned in soft agar. The 
expression of recombinant receptors by cloned cells was assessed 
by indirect immunofluorescence. The expression of recombinant re- 
ceptors on clones remained stable over the duration of experiments. 
Several clones of each transfectant were used for experiments. They 
gave similar results. 
RT-PCR Analysis 
Total RNA (2 ug), isolated from cells by the guanidine-thiocyanate 
method as described (Chomczinski and Sacchi, 1967) were submitted 
to reverse transcriptase reaction for 1 hr at 42OC with 1 uM oligo(dThs 
primer, 20 U AMV reverse transcriptase, and 50 U RNase inhibitors 
(Boehringer). PCR amplification (30 cycles) was applied with adenatur- 
ing temperature of 94OC (for 1 min), an annealing temperatureof 55OC 
(for 1 min), and an extension temperature of 72’C (for 1 min) in the 
presence of 0.2 uM of each oligonucleotide primer and 0.25 U Taq 
DNA polymerase (Perkin-Elmer Cetus, Norwalk, Connecticut). Oligo- 
nucleotides corresponding to nucleotides 909-677 and 652-661 of 
the mFcyRIIB1 cDNA sequence were used as antisense and sense 
primers, respectively. 
Indirect lmmunofluorescence 
Aliquots of 5 x lo5 cells were incubated for 1 hr at O°C with 10 pg/ 
ml MAb to receptors to be examined, in HBSS (GIBCO BRL) containing 
5% FCS (HBSS-FCS), or with HBSS-FCS alone. They were washed 
and stained by being incubated for 30 min at O°C with 50 uglml FITC- 
labeled F(abr)* fragments of polyclonal anti-immunoglobulin antibod- 
ies, in HBSS-FCS. Fluorescence was analyzed by flow cytometry us- 
ing a FACScan (Becton-Dickinson, Montain View, California). Cells 
expressing wild-type or mutated mFcrRllB were incubated with 2.462 
and stained with FITC-MAR F(ab’h. Transfectants expressing wild- 
type or mutated hFcyRllB were incubated with AT10 or IV.3 and 
stained with FITC-GAM F(ab’),. Cells expressing a murine TCR were 
incubated with 2Cll and stained with FITC-GAM F(ab’),. Transfec- 
tants expressing Tat chimeras were incubated with 7G7 and stained 
with FITC-GAM F(ab’)*. 
Serotonin Release and Assay 
Transfected or nontransfected RBL-2H3 cells, resuspended in RPM1 
medium supplemented with 10% FCS (RPMI-FCS) at 1 x 106 cells/ 
ml, were incubated at 37OC for 1 hr with 2 uCi/ml [3H]serotonin (Amer- 
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sham, Les Ulis, France), washed, resuspended in RPMI-FCS, incu- 
bated for another 1 hr at 37OC to remove excess [3H]serotonin, washed 
again, resuspended in the same medium, distributed in 96-well micro- 
culture plates at 2 x 105 cells/well, and incubated for 1 hr at 37OC 
with IgE or 7G7 F(ab), in a final volume of 50 11. Adherent cells were 
washed four times with 200 ul HESS, 25 pi culture medium was added 
to each well, and cells were warmed at 37OC for 15 min before chal- 
lenge. Cells were challenged for 30 min at 37°C with 25 ul MAR F(ab’)* 
or GAM F(ab)n, previously warmed at 37OC for 15 min. Reactions were 
stopped by adding 50 ul ice-cold medium and by placing plates on 
ice. Supernatants (50 ul)were mixed with 200 ul Aqualuma-Plus scintil- 
lation fluid (Lumac, The Netherlands) and counted in a P-plate counter 
(Pharmacia, Uppsala, Sweden). The percentage of [3H]serotonin re- 
lease was calculated using as 100% cpm in 50 ul harvested from wells 
containing the same number of cells that were lysed in 108 ul of 0.5% 
SDS and 0.5% NP40. 
Histamine Release and Assay 
Histamine release was studied in human basophils, which do not con- 
tain serotonin. Acid-treated purified human basophils were sensitized 
for 90 min at 37°C with mouse IgE. They were washed, warmed for 
30 min at 37OC, challenged with 25 r(g/ml GAM F(ab’h, and histamine 
released in supernatants was measured by fluorometric analysis as 
described (Pasmans et al., 1994). 
IL-2 Synthesis and Assay 
Aliquots of 1 x 105 284 or RMA cells were incubated with various 
concentrations of 2.C11, 2.4G2, or both for 1 hr at 0°C. Cells were 
washed, resuspended in culture medium, warmed at 37OC for 15 min. 
and added to GAM F(ab$-coated plates. These were 96-well culture 
plates previously coated for 2 hr at room temperature with GAM F(ab’)* 
diluted at 50 uglml in phosphate-buffered saline and saturated with 
culture medium containing 10% FCS for 1 hr at 37°C. After a 12 hr 
incubation at 37OC, cell-free supernatants were harvested and as- 
sayed for IL-2 on CTLL-2 cells as described (Gillis and Smith, 1977). 
Aliquots of 1 x IO5 BW5147-66 transfectants were placed in 2C11 
F(ab$- and/or 2.4G2 F(ab’),-coated plates for stimulation. These were 
96-well ELISA plates previously coated for 2 hr at room temperature 
with 2Cll F(ab’), and/or 2.4G2 F(ab’)*, diluted in phosphate-buffered 
saline at various concentrations, and saturated with culture medium 
containing 10% FCS for 1 hr at 37OC. After a 6 hr incubation, cells 
were transfered into noncoated 96-well culture plates and further incu- 
bated for 12 hr at 37OC. Cell-free supernatants were harvested and 
assayed for IL-2 on CTLL-2 cells. 
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